Fiscal Year 2019 – Record year points to increasing growth dynamics

March 13, 2020
  • Sales pass 300-million mark for the first time at 313.7 million CHF
  • EBIT margin rises to 19.9%, EBITDA margin to 27.8%
  • Net income up sharply to 54.2 million CHF
  • Initial successes in oligonucleotide market
  • Growth targets raised thanks to rising demand
  • Proposed dividend increase to 3.00 CHF per share

test theme builder local clear 256mb